Curanex Pharmaceuticals CURX
NASDAQ CURX
$4.71 -0.56 (-10.63%)
At close: Aug 21, 2026 · 4:00 PM EDT

Curanex Pharmaceuticals (CURX) Liabilities and Shareholders Equity (2024 - 2025)

Curanex Pharmaceuticals' (CURX) quarterly Liabilities and Shareholders Equity came in at $11.6 million in Q4 2025, up 2135.83% YoY from $517935.0 in Q4 2024, and down 20.02% on a QoQ basis from $14.5 million in Q3 2025.

Curanex Pharmaceuticals (CURX) Liabilities and Shareholders Equity (2024 - 2025) Analysis & Trends

Curanex Pharmaceuticals (CURX) has 2 years of Liabilities and Shareholders Equity data on file, last reported at $11.6 million in Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 2135.83% year-over-year to $11.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $27.4 million (changed N/A YoY) and the FY2025 annual result came in at $11.6 million, up 2135.83% from the prior year.
  • Liabilities and Shareholders Equity fell to $11.6 million in Q4 2025, from $14.5 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $14.5 million in Q3 2025 to a low of $517935.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 10.03 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 10.96 Bn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 9.18 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 5.56 Bn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 25.60 Bn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 2.10 Bn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 19.82 Bn
10 Curanex Pharmaceuticals 6.02 Mn 1.02 Mn - 11.58 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 11.58 Mn
Sep 30, 2025 14.48 Mn
Jun 30, 2025 787,174.00
Dec 31, 2024 517,935.00